Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

By sjmartinez • February 17, 2023

Garassino MC, Gadgeel S, Novello S, Halmos B, Felip E, Speranza G, Hui R, Garon EB, Horinouchi H, Sugawara S, Rodriguez-Abreu D, Reck M, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Piperdi B, Pietanza MC, Paz-Ares L. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO Clin Res Rep. 2022 Nov 8;4(1):100431. doi: 10.1016/j.jtocrr.2022.100431. PMID: 36793385; PMCID: PMC9923193.

Tags: Biomarker, Hematology/Oncology, Metastatic non‒small-cell lung cancer, pembrolizumab, Publications, Single-gene genetic alterations, Tissue tumor mutational burden

Related Posts

Linking Baseline PSMA PET-Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study

Murthy V, Kimura K, Theus L, Nguyen A, Grogan TR, Lokre O, Perk T, Rettig MB, Drakaki A, Shen J, Thin P, Nguyen K, Lira[...]

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

Wainberg ZA, Link JM, Premji A, Zheng S, Srienc M, Hammons M, Kim SE, Li L, Liu Z, Tsvetkova O, Abt ER, Rosen L, Kim[...]

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma

O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ,[...]